This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pfizer Needs to Think About Splitting: Goldman

Stocks in this article: PFE ABT COV KFT

NEW YORK ( TheStreet) -- After cutting a string of mega mergers, Pfizer (PFE) may be the next Dow Jones Industrial Average component to consider a breakup to unlock the value of its waning shares.

It's the thought that Goldman Sachs argues in a Tuesday research report, as others in the pharmaceuticals and healthcare space like Abbott Laboratories (ABT) and Covidien (COV) pursue multi-billion spinoff plans. Already, Pfizer is headed in the direction of consolidation after putting its animal healthcare and baby nutrition units on the selling block.





After meeting with Pfizer Chief Executive Ian Read, Goldman Sachs analyst Jami Rubin says that the world's largest drug maker may take bigger breakup steps than just a sale of its animal health and nutrition units. "We recently met with PFE's CEO Ian Read, who expressed an openness to going further with separations beyond Animal Health and Nutrition if the conditions make sense... This, coupled with the CEO's openness to consider unlocking further value, could create an attractive situation with significant upside," wrote Rubin of the meeting.

If Pfizer were to undergo a full breakup Rubin expects it to occur in three parts, with a previously stated intention to separate the New York-based company's animal health and nutrition units being the first step. In July, CEO Read said that Pfizer was exploring strategic alternatives for its animal health and nutrition units. Recent media reports signal that Danone of France and Mead Johnson (MJN) could bid on Pfizer's nutrition business for $10 billion. March reports also signal that Bayer (BAYRY) could bid up to $18 billion for Pfizer's animal health unit.

Rubin added new twists to Pfizer deal rumors in his report of talks with Read. "Mr. Read believes the most likely scenario to be a sale of Nutritionals and an IPO/split-off of Animal Health, reiterating that "buybacks will be the case to beat," wrote Rubin.

In a split, Pfizer would be more focused on its growth oriented pharmaceuticals business and a stable generics business, argues Rubin, who sees the moves netting Pfizer 18 cents a share in earnings per share. A second step would then be a rationalization of Pfizer's organizational structure after the disposals with efficiency efforts likely to wrench out a $26 a share stock value that puts Pfizer on Goldman Sachs' "America's conviction buy list."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs